Halozyme Share Price

Halozyme Share Price

NASDAQ: HALO | Large Cap | Healthcare
$91.37
-$1.62 (-1.74%) Last updated on 21 Nov, 2026 | 02:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Halozyme Stock Performance

Open
$93.48
Prev. Close
$92.99
Circuit Range
N/A
Day Range
$90.95 - $93.52
Year Range
$61.24 - $133.79
Volume
82,305
Average Traded
$92.18

Halozyme Share Price Today

As of 21 November 2026, Halozyme Therapeutics, Inc.'s share price is $91.37. The stock opened at $93.48, compared to its previous close of $92.99. During today's trading session, Halozyme Therapeutics, Inc.'s share price traded between $90.95 and $93.52, with an average price of $92.23. Over the past 52 weeks, the stock has recorded a high of $133.79 and a low of $61.24. In terms of performance, Halozyme Therapeutics, Inc.'s share price has risen by 37.30% over the last six months and is up 27.84% on a year-on-year basis.

Halozyme Share Price Chart

Line chart of the Halozyme price trend over the selected period. The price fell overall, ranging from 91.04 to 93.55, ending at 91.39.
$90.95$93.52
L
Show Current Price
H

Halozyme Stock Fundamentals & Key Indicators

Market Cap
$10.95B
PE Ratio (TTM)
21.85
Dividend Yield
0.00%
EPS (TTM)
$4.26
Revenue (TTM)
$1.40T
Return On Equity (TTM)
-878.76%
Profit Margin
22.69%
Debt to Equity
-58.84
Quarterly Earnings Growth YoY
274.48%

Halozyme Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$451.77$376.71$481.00$492.97
Net Profit-$141.59$150.05$229.91$247.05
Net Profit Margin-31.34%39.83%47.80%50.11%
Income ChangeN/A205.97%53.22%7.46%

Halozyme Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$660.12$829.25$1015.32$1396.61
Net Profit$202.13$281.59$444.09$316.89
Net Profit Margin30.62%33.96%43.74%22.69%
Income ChangeN/A39.31%57.71%-28.64%

Halozyme Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets1700.12978.14986.851102.5
Current Assets825.211085.34746.42739.01
Total Assets2525.322063.481733.271841.51
Non Current Liabilities2299.421560.561536.971540.92
Current Liabilities177.09139.1112.49130.79
Total Liabilities2476.511699.661649.461671.71
Shareholders' Equity48.81363.8283.81169.8

Halozyme Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating651.56479.06388.57240.11
Investing-545.81-262.72-96.91-487.01
Financing-85.17-218.86-407.99362.37

About Halozyme

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Halozyme Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$130.56
$91.33
-30.18%
Oct 2026
$109.57
$130.81
+18.36%
Sep 2026
$107.94
$110.52
+3.37%
Aug 2026
$82.42
$106.92
+29.55%
Jul 2026
$78.42
$82.53
+5.53%
Jun 2026
$66.10
$78.21
+17.52%
May 2026
$63.41
$66.55
+4.56%
Apr 2026
$64.74
$63.65
-1.49%
Mar 2026
$69.05
$64.61
-7.09%
Feb 2026
$71.64
$69.55
-2.91%
Jan 2026
$67.73
$71.63
+6.47%
Dec 2025
$71.77
$67.28
-5.86%

Halozyme Share Price FAQs